ELOQUENT-3 trial: what clinicians have said so far
An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethasone With or Without Elotuzumab to Treat Refractory and Relapsed and Refractory Multiple Myeloma (ELOQUENT-3)
- NCT02654132 ↗
- Completed
- Bristol-Myers Squibb
- Deep size, estimated: 301+ verified statements once built
We haven't built an HCP commentary report on ELOQUENT-3 (elotuzumab in relapsed and refractory multiple myeloma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Some of the questions raised in the 19 most recent indexed sources
Automated from the 19 newest of 22 indexed sources (Aug 2018 – Apr 2025). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice.
- Whether elotuzumab-pomalidomide-dexamethasone retains a role after daratumumab or other anti-CD38 exposure or refractoriness
- How to interpret the overall survival analysis of elotuzumab plus pomalidomide-dexamethasone
- Whether pomalidomide-dexamethasone remains an appropriate control arm, and how it performed versus other trials
- Whether elotuzumab-pomalidomide-dexamethasone can be compared across trials with daratumumab- or isatuximab-pomalidomide-dexamethasone
Indexed commentary on ELOQUENT-3 so far
Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 18 posts on X, typically up to 79 once built | |
| 2 YouTube videos, typically up to 9 once built | |
| 2 podcast episodes, typically up to 9 once built |
The trial
ClinicalTrials.gov- Official title
- An Open Label, Randomized Phase 2 Trial of Pomalidomide/Dexamethasone With or Without Elotuzumab in Relapsed and Refractory Multiple Myeloma (ELOQUENT-3)
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Multiple Myeloma
- Interventions
- Elotuzumab; Pomalidomide; Dexamethasone
- Arms
- Elotuzumab Arm · Experimental
- Control Arm · Active comparator
- Enrollment
- 117
- Primary outcomes
- Progression Free Survival (PFS)
- Sponsor
- Bristol-Myers Squibb with Celgene, AbbVie
- Start
- Mar 18, 2016
- Primary completion
- Jan 17, 2018
- Results posted
- Yes
- Registry record
- NCT02654132 · updated Nov 1, 2022
Publications
linked from the registry- Dimopoulos MA, Dytfeld D, Grosicki S, Moreau P, Takezako N, Hori M, Leleu X, LeBlanc R, Suzuki K, Raab MS, Richardson PG, Popa McKiver M, Jou YM, Yao D, Das P, San-Miguel J. Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial. J Clin Oncol. 2023 Jan 20;41(3):568-578. doi: 10.1200/JCO.21.02815. Epub 2022 Aug 12. PubMed 35960908
- Dimopoulos MA, Dytfeld D, Grosicki S, Moreau P, Takezako N, Hori M, Leleu X, LeBlanc R, Suzuki K, Raab MS, Richardson PG, Popa McKiver M, Jou YM, Shelat SG, Robbins M, Rafferty B, San-Miguel J. Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma. N Engl J Med. 2018 Nov 8;379(19):1811-1822. doi: 10.1056/NEJMoa1805762. PubMed 30403938